Asia Pacific CDMO Market Size and Share Outlook Report: Forecast Trends and Growth Analysis (2026-2035)

What is the Asia Pacific Contract Development and Manufacturing Organization (CDMO) Market Overview?

Contract Development and Manufacturing Organizations (CDMOs) offer end-to-end solutions to pharmaceutical and biotechnology companies, encompassing drug development, manufacturing, and related services. These organizations enable firms to accelerate product timelines, optimize costs, and access specialized expertise without expanding internal infrastructure. The CDMO market in Asia Pacific is experiencing robust growth, driven by strong regional manufacturing capabilities, favorable regulatory environments, and increasing demand for cost-effective drug development. Rising investments in biologics and personalized medicine further support market expansion. The market was valued at USD 64.78 Billion in 2025, with growth fueled by strategic collaborations, rising exports, and increasing pharmaceutical outsourcing across the region.

What are the Drivers for Asia Pacific Contract Development and Manufacturing Organization Market (CDMO) Growth?

One of the key drivers of this growth is the increasing incidence of chronic and preventable diseases across Asia Pacific, prompting pharmaceutical companies to outsource drug development and manufacturing to specialized CDMOs. For example, the rising burden of cervical cancer in the region has become a significant concern. According to Roche, over half of global cervical cancer deaths occur in Asia-Pacific, with projections indicating a further rise in the coming decade. This growing health challenge underscores the urgent need for efficient therapeutic development, thereby amplifying the role of CDMOs in ensuring faster, scalable, and cost-effective production, ultimately driving market expansion.

Another major growth driver is the ongoing expansion in API manufacturing capacity across the region. To meet increasing global demand for high-quality and high-potency APIs, several CDMOs are investing in technologically advanced infrastructure. Notably, in February 2023, Piramal Pharma Solutions announced the launch of initial production batches at its newly expanded API facility in Riverview, Michigan. The facility, part of the USD 38 million Project PRIME Phase 1, significantly enhanced the company’s capability to produce high-potency APIs and scale clinical trial materials. This development reflects a broader regional push to expand manufacturing capabilities, reinforcing the strategic importance of CDMOs and propelling market growth.

What are the Key Asia Pacific Contract Development and Manufacturing Organization (CDMO) Market Trends?

The market is experiencing several emerging trends, notably the rise of strategic collaborations in cell and gene therapy CDMO services.

Strategic Collaborations in Cell and Gene Therapy CDMO Expected to Boost Asia Pacific Market Value

The formation of strategic partnerships aimed at enhancing cell and gene therapy capabilities is a notable trend in the market. For instance, in October 2024, Teijin Limited and Singapore-based Hilleman Laboratories signed a Memorandum of Understanding to expand CDMO services across the region. This partnership focuses on supporting Japanese clients entering Asia-Pacific and attracting overseas clients to Japan. Such initiatives are likely to significantly boost market growth in the Asia Pacific region.

Asia Pacific Contract Development and Manufacturing Organization (CDMO) Market Share

Contract Manufacturing Organizations Expected to Dominate the Market

The Asia Pacific CDMO market is segmented by service type into contract manufacturing organizations (CMOs) and contract research organizations (CROs). While both segments play vital roles, the CMO segment is expected to lead the market due to its robust growth trajectory. According to the EMR report, the CMO segment reached USD 41.39 billion in 2024 and is projected to grow significantly, reaching USD 122.42 billion by 2034 at a CAGR of 11.8%. This growth is fueled by increasing demand for advanced therapeutic solutions and the rising outsourcing of manufacturing activities by pharmaceutical companies.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Asia Pacific Contract Development and Manufacturing Organization (CDMO) Market Analysis by Region

The CDMO market in Asia Pacific includes prominent regions such as China, India, Japan, ASEAN, Australia, and others. Among these, China is expected to hold a significant share in the market, supported by its advanced manufacturing capabilities, cost-effective operations, favorable government policies, and rapid growth in the biologics and pharmaceutical sectors. According to EMR report, China’s CDMO segment is projected to increase from USD 22.98 billion in 2025 to USD 62.02 billion by 2034, registering a robust CAGR of 11.7%.

Who are the Leading Players in the Asia Pacific Contract Development and Manufacturing Organization (CDMO) Market?

Other key players in the market include Boehringer Ingelheim, Famar SA, Lonza Group, Novotech Pty Ltd., WuXi AppTec, Fareva SA, FUJIFILM Diosynth Biotechnologies, Nipro Pharma Corporation, B. Braun SE, and WuXi Biologics.

What is the Asia Pacific Contract Development and Manufacturing Organization (CDMO) Market Segmentation?

Key Questions Answered in the Asia Pacific Contract Development and Manufacturing Organization (CDMO) Market Report

• What was the Asia Pacific CDMO market value in 2025?
• What is the Asia Pacific CDMO market forecast outlook for 2026-2035?
• What are the major factors aiding the Asia Pacific CDMO market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major Asia Pacific CDMO market trends?
• Which service type is expected to dominate the market segment?
• Which therapeutic area is projected to lead the market segment?
• Which end user is likely to dominate the market segment?
• Who are the key players involved in the Asia Pacific CDMO market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Key Benefits for Stakeholders

• Expert Market Research's report provides a detailed quantitative analysis of various market segments, historical and current trends, forecasts, and dynamics within the Asia Pacific CDMO market from 2018 to 2034.
• The report offers up-to-date information on key market drivers, challenges, and opportunities in the global healthcare interoperability solutions sector.
• The report uses Porter's five forces analysis to assess the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitutes, helping stakeholders evaluate the level of competition and market attractiveness.
• The competitive landscape section allows stakeholders to understand the competitive environment and provides insights into the current positions of key players in the market.